Autolus Therapeutics (AUTL) Current Assets (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of Current Assets data on file, last reported at $435.9 million in Q4 2025.

• For the quarter ending Q4 2025, Current Assets fell 34.05% year-over-year to $435.9 million; the trailing twelve-month figure through Dec 2025 stood at $435.9 million (down 34.05% YoY), and the FY2025 full-year result was $435.9 million, down 34.05% from the prior year.
• Current Assets for Q4 2025 stood at $435.9 million, down from $514.6 million in the prior quarter.
• Across five years, Current Assets topped out at $804.3 million in Q1 2024 and bottomed at $212.3 million in Q3 2022.
• The 5-year median for Current Assets is $374.6 million (2023), against an average of $438.2 million.
• The widest annual swing landed in 2023, when Current Assets sank 35.34%; it then soared 140.07% in 2024.
• A 5-year view of Current Assets shows it stood at $347.0 million in 2021, then advanced by 22.72% to $425.8 million in 2022, then tumbled by 35.34% to $275.3 million in 2023, then jumped by 140.07% to $660.9 million in 2024, then plunged by 34.05% to $435.9 million in 2025.
• The last three Current Assets figures came in at $435.9 million (Q4 2025), $514.6 million (Q3 2025), and $574.2 million (Q2 2025), per Business Quant data.

Peer Comparison